thought leadership
Transforming the HS patient experience: Why innovative treatments alone aren’t enough
September 4, 2024
Hidradenitis suppurativa (HS) is a common but underdiagnosed dermatological condition that causes recurring abscesses, scarring, and chronic suppuration. Approximately 240,000 people in North America are diagnosed with HS each year, but experts believe this is only around 1% of all cases.
Of those diagnosed, just half of patients respond to the biologics on the market, leaving many people with limited options. But this is about to change. With numerous treatments in clinical trials, global biopharmaceutical companies are poised to make a significant difference to the lives of patients with HS.
Despite the innovation in the pipeline, several persistent barriers remain across the patient journey that prevent people from receiving diagnosis, treatment, and care. Biopharmaceutical companies will need to solve these challenges if they are to ensure novel therapies reach every patient with HS.
Collaborating with world-leading dermatologists at our Expert Partnership FIDE, our HS experts have developed a new infographic providing clinical perspectives on the landscape and advice on improving the patient experience.
Download the infographic to uncover:
- Pain points across the HS diagnostic and treatment journey
- Three significant unmet patient needs
- Exclusive analysis from leading dermatologists
- Recommendations for meeting patients at the moments that matter.
- How you can meet the FIDE faculty, and gain insights into HS and other dermatological diseases at EADV
